Searched for
PARAS PHARMACEUTICALS
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsGiven the state of the market these days, it would be wise to be selective. Not only in terms of stocks, but also in terms of sectors. For ...- India launches anti-dumping probe into electrical steel imports from China, 3 other nationsIndia has launched an anti-dumping investigation into electrical steel imports from China, Japan, Korea, and Russia. This move, prompted by...
- Time to be selectively bullish again? 5 small-cap stocks from different sectors with upside potential of up to 29%The conditions that created the worst 18 months for small-caps are starting to ease. The US-Iran war is moving towards settlement. Crude pr...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 27%, according to analystsWe are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...
- Cancer drug prices raised 50% as NPPA acts on shortage concernsIndia's drug pricing authority has approved a 50% price hike for essential anti-cancer drugs carboplatin and cisplatin. This decision follo...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 26%Just look at developments in the past 48 hours. The war between Iran and Israel resumed, but within hours Tehran said it had halted all off...
- Drug companies directed to step up vigil on adverse reactionsIndia's drug regulator, CDSCO, has mandated all drug companies to establish systems for tracking adverse drug reactions. This move comes am...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsThe latest escalation in the US-Iran war means that crude oil price is back as a risk for India. Although we are in a market already strugg...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...
- Vini Cosmetics in talks with Apax, TA Associates & Advent to sell minority stakeVini Cosmetics, started by Darshan Patel, who was among the family promoters of Paras Pharmaceuticals, manufactures personal care, pharmace...
- Vini Cosmetics promoter Darshan Patel plans to raise Rs 400 crore to fund buyoutsPatel is one of the three brothers who managed Paras Pharmaceuticals that had OTC brands like Itch-Guard, Krack, Moov and personal care bra...
- Ex-Paras Pharmaceuticals executives launch cosmeceutical startupThree former top executives of Paras Pharmaceuticals, the Ahmedabad company that owned brands such as Moov, Itch Guard and Dermicool, are b...
- Eyeing to buy Paras' personal care: EmamiEmami on Sunday said it is in talks with global FMCG giant Reckitt Benckiser to buy the personal care business of Paras Healthcare.
- Reckitt to absorb top Paras executivesReckitt Benckiser would absorb top 10 executives of Paras Pharmaceuticals and retain 200 people working at its Baddi plant in an in-princip...
- Reckitt Benckiser to buy Paras Pharmaceuticals for Rs 3,260 croreBritish consumer goods firm Reckitt Benckiser Group, confirmed it will buy Ahmedabad-based Paras Pharmaceuticals for 3,260 crore ($726 mill...
- Reckitt Benckiser may snap up Paras PharmaA leading UK-based company is all set to buy Ahmedabad-based Paras Pharmaceuticals, a person close to the development said.
- Darshan Patel targets Paras Pharmaceuticals brandsDarshan Patel, the estranged brother of Paras Pharmaceuticals CMD Girish Patel, is set to take on brands such as DermiCool, ItchGuard and B...
- Japan's Taisho leads race for Paras PharmaTaisho Pharmaceuticals has emerged as the front-runner to buy a majority stake in Paras Pharmaceuticals by offering over six times the annu...
- Sequoia invests $12 mn in Paras PharmaLeading venture capital and growth equity investor Sequoia Capital India has invested $12 million in Ahmedabad-based over-the-counter (OTC)...
- Actis to buy 10% in Paras for Rs 100 crPrivate equity major Actis is close to picking up 10% in the Ahmedabad-based Paras Pharmaceuticals, the company that owns well known brands...
Load More
